Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Two Doses of SR31747A (75 mg and 125 mg) in Non-Metastatic Androgen-Independent Prostate Cancer. Randomized, Double-Blind, Placebo Controlled Phase II Study

NCT00174863 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00174863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00174863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Two Doses of SR31747A (75 mg and 125 mg) in Non-Metastatic Androgen-Independent Prostate Cancer. Randomized, Double-Blind, Placebo Controlled Phase II Study
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2003
Completion date
August 31, 2006
Enrollment
232 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasm